A leading academic is calling on new Health Secretary Therese Coffey to reconsider rolling out a Covid drug for people with weakened immune systems.
Last month the government decided it would not supply Evusheld in the UK.
But Dr Lennard Lee, an academic medical oncologist from Oxford University who is backed by more than 120 leading scientists and clinicians, said a rethink was needed.
The government said more data was required on the treatment.
Evusheld was approved for use in March, but was reviewed after the Omicron variant emerged.
The drug's manufacturer AstraZeneca said there was "ample real-world data" that it worked. It is currently available in 32 countries.
Dr Lee told the BBC: "It's time for a re-review of the data, and to think about transparency in terms of why they decided not to do this, and also the pros and cons of doing this.
"We do know that coronavirus cases are likely to go up in winter, and we do know there are people who face increased risks…
"Therefore if there is anything we can do to protect… anyone immunosuppressed I think this is something that does need to be reconsidered."
Research from the US and Israel suggests Evusheld reduces the risk of infection by about 50%, and cuts the risk of serious illness by 90%.
Scientist Ketai Sithole, 44, from Oxford, had a kidney transplant four years ago and the drugs she takes suppress her immune system.
She has had five Covid jabs but antibody tests show she is still unprotected from the virus.
She said the evidence of Evusheld's effectiveness was "more than enough".
She added: "I cannot carry on living this sheltered life.
"They say when you have a transplant the reason why you have it is to live your life fully. This is not living life fully, in some ways I feel cheated."
In a statement, the Department of Health said: "There is insufficient evidence on the duration of protection offered by Evusheld in relation to the Omicron variant.
"We are determined to support the most vulnerable and continue to explore the market for promising treatments."
The National Institute for Health and Care Excellence (NICE) is expected to issue a report on Evusheld in April.
Follow BBC South on Facebook, Twitter, or Instagram. Send your story ideas to south.newsonline@bbc.co.uk.
Campaigners call for Covid drug decision reversal
Covid antibody protection ruled out for vulnerable
AstraZeneca UK
Department of Health and Social Care
NHS England – Autumn booster
New centre for bleeding disorders opens in Oxford
Pub near Banbury needs your help to raise funds for medical vehicles to help those suffering in Ukraine
Attempted murder accused appears in court
CPRE opposes solar farm near Nuneham Courtenay
Owner is reunited with bicycle stolen from Oxford train station
Man robbed and friend attacked by group of around seven men
Crimea bridge attack arrests as market attacked
What is Vladimir Putin thinking and planning?
Jury weighing death penalty for Parkland gunman
Iran protester: 'You know you might never come back'
TikTok profits from livestreams of families begging
Iran demos: ‘If you talk, they'll put a bullet in your head’
Ice and sled-dogs disappear as Greenland warms up
Women around the world cut their hair for Iran. Video
Xi's path to a historic third term, explained
US town pays (some) black residents reparations
How mud boosts your immune system
Which Native American artefact went to space? Quiz time…
Why a 1922 horror film still terrifies
The kids being raised without gender
The phenomenon of eye colour change
© 2022 BBC. The BBC is not responsible for the content of external sites. Read about our approach to external linking.
